A financial adviser is working with the company to deliberate future plans, including a potential sale to other drugmakers, according to the April 10 report. Janux develops tumor-activated T cell therapies for cancer. Its shares quadrupled this year and has a market value of $2.3 billion, according to Bloomberg.
Janux was founded in 2017 and has four products in early research stages, according to its website.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
